Assessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research David Bender & David J. Hellerstein Psychopharmacology (Berl), 2022. Doi : 10.1007/s00213-021-06049-6 Abstract Rationale : A broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use. Objectives : To use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order [...]
Lire la suiteSerotonin and brain function : a tale of two receptors RL Carhart-Harris and DJ Nutt Journal of Psychopharmacology, 2017, Vol. 31, (9), 1091–1120. Doi : 10.1177/0269881117725915 Abstract Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and researched brain receptors: the 5-HT1A and 5-HT2A receptors. We propose that passive coping (i.e. tolerating a source of stress) [...]
Lire la suitePowerful substances in tiny amounts: Exploring the practice of microdosing psychedelic drugs Petter Grahl Johnstad, Pré-Print, 2017. This article presents an explorative study of microdosing practices with psychedelic drugs. A microdose is defined as a sub-perceptual dose, commonly about one tenth of an ordinary recreational dose, which gives no alteration of consciousness or feeling of intoxication. Respondents (n = 17) were recruited at several Internet fora for individual interviews mediated via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship and extensive entheogen experience. Respondents tended to experiment with microdosing in phases, [...]
Lire la suiteHallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Danilo De Gregorio, Argel Aguilar-Valles, Katrin H. Preller, Boris Dov Heifets, Meghan Hibicke, Jennifer Mitchell, and Gabriella Gobbi The Journal of Neuroscience, 2021, 41 (5), 891–900. Doi :10.1523/JNEUROSCI.1659-20.2020 A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as [...]
Lire la suiteFuture Directions for Clinical Psychedelic Research : The Relaxed Symptom Network Evan Lewis-Healey, Ruben Laukkonen , Michiel van Elk Pre-Print, May 2021 Doi : 10.31234/osf.io/q3ymd Abstract Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic protocol (psychedelic-assisted psychotherapy; PAP). There are now dozens of registered and ongoing clinical trials that intend to test for the efficacy of psilocybin within a psychotherapeutic protocol. Despite promising results, the mechanism(s) that may be responsible for the antidepressant effects of PAP are still hotly contested. In this paper, we provide a [...]
Lire la suiteRediscovering Psilocybin as an Antidepressive Treatment Strategy Rene Zeiss, Maximilian Gahr and Heiko Graf Pharmaceuticals, 2021, 14, 985, 1-14. doi : 10.3390/ph14100985 Abstract : There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we provide an overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks [...]
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....) 1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]
Lire la suiteCannabidiol as a Treatment for Mood Disorders : A Systematic Review Le cannabidiol comme traitement des troubles de l’humeur : une revue systématique Jairo Vinicius Pinto, MD, Gayatri Saraf, MD, Christian Frysch, MD, Daniel Vigo, MD, DrPH, Kamyar Keramatian, MD, MSc, FRCPC, Trisha Chakrabarty, MD, Raymond W. Lam, MD, Marcia Kauer-Sant’Anna, MD, PhD, and Lakshmi N. Yatham, MBBS, FRCPC The Canadian Journal of Psychiatry /La Revue Canadienne de Psychiatrie, 2020, Vol. 65, (4), 213-227. Doi : 10.1177/0706743719895195 Abstract Objective : To review the current evidence for efficacy of cannabidiol in the treatment of mood disorders. Methods : We systematically searched PubMed, Embase, Web of Science, PsychInfo, Scielo, [...]
Lire la suiteLearning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer and Henrik Jungaberle Frontiers in Psychiatry, February 2020 | Volume 11 | Article 5, 1-13. doi : 10.3389/fpsyt.2020.00005 The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled [...]
Lire la suitePsychedelic Medicines for Mood Disorders Current Evidence and Clinical Considerations Jerome Sarris; Diego Pinzon Rubiano; Kimberley Day; Nicole L. Galvão-Coelho; Daniel Perkins Current Opinion in Psychiatry, 2022, 35, (1), 22-29. doi : 10.1097/YCO.0000000000000759 https://www.medscape.com/viewarticle/964245 Abstract and Introduction Abstract Purpose of Review: Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent Findings: Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at [...]
Lire la suite